Close Menu
Merck Alliance with CST for PhosphoScan Proteomics Technology
 
Merck will use Cell Signaling Technology’s PhosphoScan technology to develop biomarker assays for its oncology therapeutics program under an alliance announced this week.
 
The PhosphoScan technology allows for the discovery of drug target phospho-profiles in cells and disease tissues. CST will also provide Merck its expertise in antibody development and validation to develop high specificity biomarker assays.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.